close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Becton Dickinson (NY:BDX)

189.10 +3.83 (+2.07%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Becton Dickinson

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023
 
Via Benzinga
Dividend Income Update March 2023
It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio. 
Via Talk Markets
The Latest Analyst Ratings for Becton, Dickinson
 
Via Benzinga
Becton, Dickinson's Debt Overview
 
Via Benzinga
(BDX) - Analyzing Becton, Dickinson's Short Interest
 
Via Benzinga
Looking Into Becton's Return On Capital Employed
 
Via Benzinga
7 Dividend Aristocrats to Buy for Consistent Income Growth
The dividend aristocrats each provide consistent income growth over the long-term that those seeking passive income can rely on. 
Via InvestorPlace
3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term Potential
These three spinoffs are already profitable. 
Via The Motley Fool
Healthcare Stocks With at Least 30 Years of Dividend Increases
Among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield. 
Via MarketBeat
3 Stocks To Buy For Consistent Dividend Growth
One way to avoid some of the volatility in the stock market is to buy old companies that have a long history of raising dividends. These are companies with iconic brands, lasting products, and... 
Via Talk Markets
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?
By David Willey, Benzinga 
Via TheNewswire.com
What 6 Analyst Ratings Have To Say About Becton, Dickinson
 
Via Benzinga
A Bullish Sign Appears On Becton, Dickinson's Chart
 
Via Benzinga
What 6 Analyst Ratings Have To Say About Becton, Dickinson
 
Via Benzinga
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company? 
Via News Direct
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?
The medical device and supply manufacturing industry is focused on the design and production of medical instruments and devices. 
Via Benzinga
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its 
Via MarketBeat
Topics Initial Public Offering
The 7 Best Dividend Growth Stocks for Long-Term Investors
Although passive income is always useful under uncertain times, why not get capital gains through the best dividend growth stocks? 
Via InvestorPlace
2 Medical Stocks to Watch Heading Into 2023
The two healthcare companies easily outdid the S&P 500 this year. 
Via The Motley Fool
Embecta Stock Tumbles On Mixed Q4 Results, Softer Guidance
 
Via Benzinga
Becton Dickinson Reports Cybersecurity Vulnerabilities For Alaris Infusion Monitoring Software
Becton Dickinson and Co (NYSE: BDX) issued a voluntary notification regarding cybersecurity vulnerabilities with its Alaris Infusion Central software. 
Via Benzinga
With COVID-19 Having Placed A Sharp Focus On Syringes, This Innovator Looks Back At A Year Of Successes Since Their 2022 IPO
Medical device company Sharps Technology Inc. (NASDAQ: STSS) is taking stock as it approaches one year since its initial public offering (IPO). Since its IPO, the company has taken major strides in... 
Via Benzinga
Why Embecta Stock Popped by Nearly 13% Today
Twin beats and raised guidance make for a good day on the market for the diabetes care specialist. 
Via The Motley Fool
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
By David Willey, Benzinga 
Via TheNewswire.com
Topics Economy
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products 
Via News Direct
Topics Economy
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
Sharps Technology, Inc. (NASDAQ: STSS) recently announced that the Company will be commercializing cutting-edge prefillable syringe system products to provide new solutions to customers in the... 
Via Benzinga
Global Drug Delivery Systems Market Size Projected to Reach $71.75 Billion By 2029
EQNX::TICKER_START (NASDAQ:STSS),(NYSE:BDX),(NYSE:CAH),(NYSE:NVO),(OTCPK:TRUMY),(NASDAQ:STSSW) EQNX::TICKER_END 
Via FinancialNewsMedia
Becton Dickinson, Freeport-McMoRan, GXO Logistics And This Mid-Cap ETF On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named iShares Core S&P Mid-Cap ETF (NYSE: IJH), saying that "mid-c 
Via Benzinga
Sharps Technology Is Injecting A Better Solution Into The Healthcare Syringe Industry
Medical device company Sharps Technology, Inc. (NASDAQ: STSS) is closing out a successful year after its April initial public offering (IPO) on the NASDAQ market. The company focuses on the development... 
Via Benzinga
2 Relatively Safe Dividend Stocks to Buy Today and Hold Forever
They already have extensive track records of success, and there's even more on the way. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today